A kind of preparation method of highly pathogenic h7n9 avian influenza virus, vaccine, detection reagent and virus, vaccine
An avian influenza virus, highly pathogenic technology, applied in antiviral agents, botanical equipment and methods, biochemical equipment and methods, etc., can solve the problem of insufficient protection, low safety, and low vaccine immunogenicity. question
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0052] Preparation method of highly pathogenic H7N9 avian influenza virus with high immunogenicity
[0053] The first step is to synthesize the HA gene:
[0054] First, according to the HA gene sequence of the highly pathogenic H7N9 avian influenza virus vaccine strain A / Guangdong / 17SF003 / 2016 (H7N9) recommended by WHO, synthesize the HA gene with multiple basic amino acid deletions at the cleavage site, and multiple bases at the cleavage site The HA gene (referred to as H7 / GD16 / WT) with sex amino acid deletion was completed by GenScript. Existing studies have shown that the cleavage site with multiple basic amino acids is a sign of highly pathogenic avian influenza virus, and the deletion of multiple basic amino acids can reduce its pathogenicity, so that the recombinant virus can be tested in the biosafety level two experiment. The operation is carried out in the room without affecting the immunogenicity of the HA protein. For safety reasons, the cleavage site in the HA ge...
Embodiment 2
[0069] The difference between Example 2 and Example 1 is that the NA fragment in Example 2 is selected from the NA gene of the N9 subtype without oseltamivir resistance mutation. The N9 subtype NA gene containing the oseltamivir resistance mutation has the effect of oseltamivir resistance, and the highly immunogenic and highly pathogenic H7N9 avian influenza virus prepared by using the mutated NA gene and the corresponding The vaccine has the risk of causing the proliferation of drug resistance genes. By using non-oseltamivir drug resistance mutated NA genes, the widespread dissemination of oseltamivir drug resistance mutated NA genes can be avoided. The synthesis of HA gene of H7 / GD16 / WT, the construction of pM-H7 / GD16 / WT recombinant plasmid and the site-directed mutation of HA gene in Example 2 are all the same as in Example 1 above.
[0070] The first step, NA gene synthesis:
[0071] The NA gene was selected from the NA gene (GISAID ID: EPI439509, called N9 / AH13) of the l...
Embodiment 3
[0084] The preparation method of highly pathogenic H7N9 avian influenza inactivated vaccine with high immunogenicity comprises an inactivation step and a purification step.
[0085] The first step, inactivation of influenza virus
[0086] The two recombinant influenza viruses prepared in Example 2 above were inactivated, and the specific inactivation method was as follows. Formaldehyde solution was used for inactivation, and formaldehyde solution with a final concentration of 0.1% was added to the virus allantoic fluid, and inactivated at 37° C. for 16 hours. The inactivated influenza virus was continuously passaged in chicken embryos for three times, and it was determined that the inactivation was successful if no hemagglutination titer was detected after passage.
[0087] The second step, the purification of influenza virus
[0088] The inactivated influenza virus chicken embryo allantoic fluid was centrifuged at 120000×g for 1.5 h in an ultracentrifuge to concentrate the ...
PUM
Property | Measurement | Unit |
---|---|---|
concentration | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com